BIOMAT Database Logo BIOMAT Database Logo

Treatment of transplanted spontaneous rat T-cell leukaemia with local administration of recombinant murine interleukin-2. 1997

B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Department of Biology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

Spontaneous rat CD4+CD8-T-cell leukaemia transplanted in syngeneic recipients served as an experimental model system for IL-2 therapy. As a source of IL-2, supernatants from in vitro cultured plasmacytoma cell line X63-m-IL2 secreting constitutively recombinant murine IL-2 were utilized. Administration of IL-2, s.c. to the vicinity of the tumour inoculum, suppressed tumour growth. The tumour-inhibitory IL-2 effects were time- and dose-dependent. When the treatment has started 10 days after the challenge with 10(4) leukaemia cells, IL-2 inhibitory effects on the lymphoma growth in situ were demonstrated by lower tumour weight combined with necrotic changes. No histological signs of lymphoma generalization were found in parenchymatous organs of IL-2-treated rats in contrast to the untreated controls. No histological or functional injuries to the kidneys due to IL-2 administration were found. The results of effector cell phenotyping demonstrated the kinetics of the CD4+/CD8+ ratio characterized by CD4+ T-cell depletion and resulting increase in the percentage of CD8+ PBL.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010954 Plasmacytoma Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites. Plasma Cell Tumor,Plasmocytoma,Plasma Cell Tumors,Plasmacytomas,Plasmocytomas,Tumor, Plasma Cell,Tumors, Plasma Cell
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014185 Transplantation, Isogeneic Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains. Transplantation, Syngeneic,Isogeneic Transplantation,Isograft Transplantation,Isografting,Syngeneic Transplantation,Transplantation, Isograft
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015458 Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood. Leukemia, Lymphocytic, T-Cell,Lymphocytic Leukemia, T-Cell,T-Cell Leukemia,T-Lymphocytic Leukemia,Leukemia, Lymphocytic, T Cell,T Lymphocytic Leukemia,Leukemia, T Cell,Leukemia, T Lymphocytic,Leukemia, T-Cell Lymphocytic,Leukemia, T-Lymphocytic,Leukemias, T Lymphocytic,Leukemias, T-Cell,Leukemias, T-Cell Lymphocytic,Leukemias, T-Lymphocytic,Lymphocytic Leukemia, T,Lymphocytic Leukemia, T Cell,Lymphocytic Leukemias, T,Lymphocytic Leukemias, T-Cell,T Cell Leukemia,T Lymphocytic Leukemias,T-Cell Leukemias,T-Cell Lymphocytic Leukemia,T-Cell Lymphocytic Leukemias,T-Lymphocytic Leukemias

Related Publications

B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
January 1986, Folia biologica,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Interleukin 2 exerts autocrine stimulation on murine T-cell leukaemia growth.
January 1997, British journal of cancer,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Spontaneous murine B-cell leukaemia.
April 1978, Nature,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Spontaneous production of interleukin 6 by adult T-cell leukaemia cells.
December 1990, British journal of cancer,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Biological activity of recombinant murine interleukin-6 in interleukin-1 T cell assays.
June 1989, Journal of immunological methods,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study.
April 1991, British journal of haematology,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Adult T-cell leukaemia with spontaneous remission.
October 1983, Lancet (London, England),
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Spindle cell hemangioendothelioma: successful treatment with recombinant interleukin-2.
June 2000, The British journal of dermatology,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).
December 2003, Gene therapy,
B Otová, and A Panczak, and J Símová, and T Jandlová, and J Bubeník, and K Blazek, and J Schramlová, and I Marinov
Treatment of hairy-cell leukaemia with recombinant human alpha 2-interferon.
May 1984, Lancet (London, England),
Copied contents to your clipboard!